Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20760274 | 0.83 | CCR6 (0.71) | CCR6 | |
| SCHEMBL20732877 | 0.83 | CCR6 (0.83) | CCR6 | |
| SCHEMBL20721315 | 0.82 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20721212 | 0.80 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20721213 | 0.80 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20721258 | 0.80 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20721141 | 0.80 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20721140 | 0.80 | CCR6 (1.00) | CCR6 | |
| SCHEMBL20760445 | 0.79 | CCR6 (0.66) | CCR6 | |
| SCHEMBL20721270 | 0.79 | CCR6 (1.00) | CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | CCR6 197/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.